Yvonne Greenstreet, Alnylam CEO

Al­ny­lam’s RNAi ther­a­py suc­ceeds in close­ly-watched Phase 3 heart tri­al

In one of the most high­ly an­tic­i­pat­ed clin­i­cal tri­al read­outs this year, an RNA si­lenc­ing treat­ment de­vel­oped by Al­ny­lam Phar­ma­ceu­ti­cals re­duced the risk of death …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.